Changes in regional gray matter volume in women with chronic pelvic pain: a voxel-based morphometry study

Sawsan As-Sanie, Richard E. Harris, Vitaly Napadow, Jieun Kim, Gina Neshewat, Anson Kairys, David Williams, Daniel J. Clauw, Tobias Schmidt-Wilcke

Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI 48109, USA
Department of Anesthesiology, Chronic Pain and Fatigue Research Center, University of Michigan, Ann Arbor, MI 48109, USA
Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, MA 02129, USA
Department of Neurology, University of Tübingen, Tübingen 07071, Germany

Abstract

Chronic pelvic pain (CPP) is a highly prevalent pain condition, estimated to affect 15%-20% of women in the United States. Endometriosis is often associated with CPP, however, other factors, such as preexisting or concomitant changes of the central pain system, might contribute to the development of chronic pain. We applied voxel-based morphometry to determine whether women with CPP with and without endometriosis display changes in brain morphology in regions known to be involved in pain processing. Four subgroups of women participated: 17 with endometriosis and CPP, 15 with endometriosis without CPP, 6 with CPP without endometriosis, and 23 healthy controls. All patients with endometriosis and/or CPP were surgically confirmed. Relative to controls, women with endometriosis-associated CPP displayed decreased gray matter volume in brain regions involved in pain perception, including the left thalamus, left cingulate gyrus, right putamen, and right insula. Women with CPP without endometriosis also showed decreases in gray matter volume in the left thalamus. Such decreases were not observed in patients with endometriosis who had no CPP. We conclude that CPP is associated with changes in regional gray matter volume within the central pain system. Although endometriosis may be an important risk factor for the development of CPP, acting as a cyclic source of peripheral nociceptive input, our data support the notion that changes in the central pain system also play an important role in the development of chronic pain, regardless of the presence of endometriosis.

Article info

Article history:
Received 16 July 2011
Received in revised form 28 December 2011
Accepted 31 January 2012
Available online xxx

Keywords:
Chronic pelvic pain
Endometriosis
Voxel-based morphometry
Thalamus
Cingulate cortex

1. Introduction

Chronic pelvic pain (CPP) is defined as “non-cyclic pain of 6 or more months’ duration that localizes to the anatomic pelvis, anterior abdominal wall at or below the umbilicus, the lumbosacral back, or the buttocks, and is of sufficient severity to cause functional disability or lead to medical care” [1]. CPP is estimated to affect 15%-20% of women in the United States, with direct health care costs approaching $2.8 billion per year [1,22]. It is the primary indication for 10% of outpatient gynecology visits, 40% of diagnostic laparoscopies, and 12%-17% of hysterectomies performed annually [18,46].

Despite its high prevalence and negative impact, little is known about the mechanisms underlying CPP. As in other chronic pain syndromes, its pathogenesis cannot be entirely explained by the presence or severity of “peripheral pathology”. For example, in women with endometriosis-associated CPP, there is little, if any, association between the severity of pain and the extent of endometriosis [5,26,43]. Medical and surgical therapies are not always effective and pain frequently recurs, often without evidence of residual disease [35,38,42]. Against this background, endometriosis must be viewed as an important but insufficient risk factor for the development of CPP.

Pain in many other chronic pain syndromes has been shown to be related to central nervous system (CNS) amplification of pain processing, which often occurs in the absence of injury or inflammation of peripheral structures [7,11,12,14,16,23]. From a neurobiological perspective, the mechanisms contributing to pain amplification and chronicity are heterogeneous and likely occur at various levels of the nervous system. In line with this evidence, structural alterations in brain regions associated with pain perception and modulation have also been identified in patients with chronic pain. The most reproducible finding is a decrease in gray matter density/volume in the thalamus, cingulate cortex, and the...
insular cortex (IC) [29,30]. It has been postulated that such changes in regional brain morphology may be responsible not only for the evolution and/or maintenance of the chronic pain state, but might also contribute to other common comorbid clinical traits, such as mood disorders and cognitive impairment [9,21,32]. Therefore, studies of brain anatomy and function might also be important for understanding the pathogenesis of CPP. The primary aim of this study was to use voxel-based morphometry (VBM) to determine whether women with CPP display changes in regional brain morphology and whether such changes are present in women with similar pelvic pathology without CPP. We investigated 3 patient subgroups: CPP and endometriosis, endometriosis but no CPP, and CPP but no endometriosis, and compared each to healthy controls. We hypothesized that CPP is associated with decreased gray matter volume in brain regions associated with pain perception and modulation, and that these differences are associated with the experience of chronic pain rather than the presence or absence of endometriosis. If this hypothesis is correct, then CPP patients (with and without endometriosis) should show gray matter changes in structures within the pain system relative to controls, and these changes would not be present in endometriosis patients without CPP.

2. Methods

2.1. Subjects

Four cohorts of participants were included: 17 women with endometriosis-associated CPP (Endo\(\times\)Pain), 15 women with "pain-free" endometriosis (Endo\(\times\)Pain, for a definition of "pain-free" see below), 6 women with CPP but no evidence of endometriosis (P\(\times\)Endo\(\times\)Pain group, surgically confirmed), and 26 healthy women (HCs [healthy controls]). For details, see Tables 1 and 2 and Fig. 1. All participants were reproductive-age women (18-52 years) who had not undergone prior hysterectomy or bilateral oophorectomy. Women with endometriosis were recruited from a tertiary-care endometriosis and pelvic pain referral center, as well as through advertisement to the local community. Inclusion criteria for endometriosis participants included a history of surgically confirmed endometriosis within 3 years of study participation. Most participants received their surgical diagnosis at another medical institution. Operative reports were reviewed by a gynecologist with significant experience in the surgical evaluation of endometriosis (S.A.) blinded to study results, and endometriosis was assigned a stage according to the revised American Fertility Society endometriosis scoring system [28]. Surgical pathology was documented when available but not required for participation because pathologic confirmation was not routinely performed in all participants. Potential participants with a history of endometriosis were screened by a telephone interview and were invited to participate only if they fell within 1 of 2 categories of pelvic pain severity: 1) chronic pelvic pain or 2) “pain-free” endometriosis. CPP was defined as moderate to severe pelvic pain that is \(\geq 4\) on a 0-10 verbal rating scale for \(\geq 6\) months duration, and was noncyclic, occurring for at least 14 days of each month, not just limited to the time of menstrual bleeding. Pelvic pain was localized to the anatomic pelvis, and could include but was not limited to only symptoms of dyspareunia (pain with intercourse), dyschezia (pain with bowel movements), or focal low back pain. "Pain-free" endometriosis was defined as the absence of any prior history of chronic pelvic pain and the absence of significant dysmenorrhea, defined as pelvic pain during menstruation that is \(\geq 4\) on a 0-10 verbal rating scale occurring for 5 or more days of each menstrual cycle (ie, all study participants falling into the Endo\(\times\)Pain group had at maximum 4 days of mild pain associated with menses). This study also included data on 6 participants with CPP but no evidence of endometriosis (Endo\(\times\)Pain). These women fulfilled all clinical criteria of CPP, had no prior surgical history of endometriosis, had undergone a diagnostic laparoscopy within 3 years of study participation, and had no surgical evidence of endometriosis or pelvic adhesions at the time of surgical exploration. No other anatomic sources of pain could be identified in these patients. Using standardized criteria, all women with endometriosis and CPP were formally screened for and excluded from participation if they had one or more of the following chronic pain syndromes thought to be associated with a central nervous system abnormality in pain processing: fibromyalgia, chronic fatigue syndrome, interstitial cystitis, chronic low back pain unrelated to pelvic pain, or temporomandibular disorder. Women with CPP had to discontinue opioid analgesia for 72 hours prior to the magnetic resonance imaging (MRI) visit.

HCs completed standardized case report forms to assess their medical history, surgical history, medication use, and any pain symptoms. All HCs were pain-free women without symptoms of dysmenorrhea, no known history of endometriosis, and no history of chronic pain (including pelvic pain or discomfort). All HCs were formally screened in a similar fashion to endometriosis participants and did not meet criteria for any of the chronic pain syndromes previously defined; and they did not have a history of chronic, recurrent headaches or irritable bowel syndrome. Women with current symptoms of major depressive disorder, bipolar disorder, general anxiety disorder (according to Diagnostic and Statistical Manual of the American Psychiatric Association IV criteria) [3] and those currently on antidepressants for any indication were excluded. HCs were recruited from ongoing studies using the same functional MRI protocol used in this study. Because the mean age of endometriosis/CPP subgroups was significantly different, each subgroup of endometriosis/CPP patients was compared to an age-matched subset of HCs in a 1:1 or 2:1 ratio (Fig. 1).

All participants had to be free of contraindications for an MRI study as determined by a health questionnaire, and were right-handed to simplify brain mapping. In order to minimize the influence of menstrual cycle variability on study results, all study visits were performed between days 2 and 10 of the menstrual cycle in women who were not using hormonal contraceptives. Additional exclusion criteria for all participants included a severe physical impairment (eg, complete blindness, deafness, paraplegia), coexisting physical injury (eg, sprained ankle, neck injury), comorbid medical illnesses (eg, morbid obesity, autoimmune diseases, cardiopulmonary disorders, uncontrolled endocrine or allergic disorders, or malignancy within 2 years), any present psychiatric disorder involving a history of psychosis, current suicide risk or attempt within 2 years of the study, substance abuse within 2 years, a pending status associated with disability or the receipt of disability compensation, being pregnant, lactating, or menopausal (defined as no menses for \(>1\) year unrelated to exogenous hormonal suppression), or a contraindication to undergoing MRI (eg, metal implants, claustrophobia).

2.2. Clinical and experimental pain

Participants with endometriosis and/or CPP completed additional standardized case report forms to assess their surgical history, medication use, and the severity, pattern, and characteristics of their pelvic pain. Measurements included numeric ratings (0-10) of pelvic pain during their menses, and the average pelvic pain intensity and unpleasantness in the last month measured with the Gracely Box Scale (GBS; Fig. 2) [13]. The GBS is a numerical scale that is used to evaluate pain intensity and unpleasantness (GBS pelvic pain intensity and unpleasantness). This scale com-

Please cite this article in press as: As-Sanie S et al. Changes in regional gray matter volume in women with chronic pelvic pain: a voxel-based morphometry study. PAIN® (2012), doi:10.1016/j.pain.2012.01.032
Table 1
Demographic and psychophysical characteristics of participant subgroups.

<table>
<thead>
<tr>
<th>Group 1: Endo Pain (n = 17)</th>
<th>Controls (n = 17)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>32.1 ± 15.7</td>
<td>25.9 ± 16</td>
</tr>
<tr>
<td>Race, white (%)</td>
<td>15 (88.5)</td>
<td>16 (94.1)</td>
</tr>
<tr>
<td>Currently using hormonal contraceptives (%)</td>
<td>10 (58.8)</td>
<td>9 (52.9)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Group 2: Endo Pain (n = 15)</th>
<th>Controls (n = 14)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild pain (kg)</td>
<td>1.14 ± 1.16</td>
<td>1.26 ± 1.24</td>
</tr>
<tr>
<td>Slight pain (kg)</td>
<td>0.32 ± 0.16</td>
<td>0.41 ± 0.16</td>
</tr>
<tr>
<td>Depression (CES-D)</td>
<td>2.0 ± 1.0</td>
<td>2.5 ± 1.2</td>
</tr>
<tr>
<td>Trait Anxiety (STPI)</td>
<td>18.3 ± 4.5</td>
<td>15.0 ± 4.0</td>
</tr>
<tr>
<td>SF-36, physical component</td>
<td>40.7 ± 10.6</td>
<td>57.9 ± 2.1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Group 3: Endo Pain (n = 6)</th>
<th>Controls (n = 12)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild pain (kg)</td>
<td>0.7 ± 0.48</td>
<td>1.08 ± 0.94</td>
</tr>
<tr>
<td>Slight pain (kg)</td>
<td>0.07 ± 0.05</td>
<td>0.12 ± 0.05</td>
</tr>
<tr>
<td>Depression (CES-D)</td>
<td>1.1 ± 1.0</td>
<td>1.2 ± 1.0</td>
</tr>
<tr>
<td>Trait Anxiety (STPI)</td>
<td>16.3 ± 3.9</td>
<td>15.0 ± 4.0</td>
</tr>
</tbody>
</table>

In a first step, each patient group was compared to its age-matched healthy control group (P-values in columns 4, 7, and 10). Further analyses (t-tests) were performed between patient groups; significant differences (P < 0.05, corrected for multiple comparisons) are marked as follows: * Endo vs. Pain; ** Endo vs. Controls; **** Endo vs. Controls (Bonferroni; P < 0.05/number of domains), yielding a threshold of P < 0.017 for 3 domains. Three domains included clinical pain, experimental pain testing, and measures of mood/function.

2.3. Depression, anxiety, and physical function

All participants completed standardized measures of depression, anxiety, and physical function. These values were used to characterize the degree of psychological distress and function of patient subgroups relative to healthy controls, and to determine if such measures of distress correlate with changes in regional gray matter (GM) volume. Depressive symptoms were measured with the Center for Epidemiological Studies Depression Scale, a 20-item self-report inventory designed to assess depressive mood [27]. Participants are asked to indicate how frequently they experienced each set of symptoms during the past week. The total possible score, ranging from 0 to 60, reflects both the number of symptoms and the frequency of their occurrence. Trait anxiety was measured using the 10-item Trait Anxiety scale from the State-Trait Personality Inventory [36]. Scores range from 10 to 40, with higher values indicating higher anxiety symptoms. Physical function and health status were measured with the SF-36, and provides individual summary scores for physical function and mental function [45]. The summary scores have been standardized to have a mean = 50, SD = 10 in the general U.S. population, with larger values indicating better function. All questionnaires were administered within 72 hours of the MRI scan.

Group differences among patients and subgroups of patients were evaluated with analysis of variance and Pearson’s χ² tests, as appropriate. Further analysis between subgroups of patients (Endo vs. Pain, Endo vs. Controls; Endo vs. Pain vs. Controls) was performed with Student’s t-test and Pearson’s χ² tests. Results were thresholded at P < 0.05, after performing a domain-specific correction for multiple comparisons (Bonferroni; P < 0.05/number of domains), yielding a threshold of P < 0.017 for 3 domains. Three domains included clinical pain, experimental pain testing, and measures of mood/function.

2.4. Scanning protocol

MRI was performed on a 3.0 Tesla GE Signa scanner (LX [VH3] release, Neuro-optimized gradients; General Electric Company, Fairfield, CT, USA). For each subject, a T1-weighted gradient echo data set (repetition time 1400 ms, time to echo 5.5 ms, flip angle 20°, field of view 256 × 256, yielding 124 sagittal slices with a defined voxel size of 1 × 1 × 1.2 mm) was acquired. An Eclipse 3.0 T 94 quadrature head coil was used. Inspection of individual T1 MR images revealed no gross morphological abnormality for any participant.

2.5. Preprocessing and statistical analysis of VBM data

The SPM5 software package (Functional Imaging Laboratories, London, UK), running under MATLAB 7b, was used to preprocess and analyze structural data [4]. Estimation of total GM volume, total white matter (WM) volume, and cerebrospinal fluid (CSF) was performed by segmenting the original image into GM, WM, and CSF, using the IBA5PM toolbox (toolbox for automatic parcellation of brain structures), provided by the Cuban Neuroscience Center [2]. Preprocessing of structural images for VBM analyses was performed using the VBM toolbox (VBM 5.1, provided by C. Gaser, default settings), which involved spatial normalization, segmentation, and spatial smoothing (Gaussian kernel of 8 mm full width at half maximum for GM images). Modulated images were used for statistical analyses; correspondingly, GM and WM values are referred to as regional GM or WM volume. Significant regional differences in GM values between groups were identified applying voxel-wise statistics within the general linear model (2-sample t-test, as appropriate). The significance threshold was set at P < 0.05. Overall group differences between characterizations of 3 subgroups of endometriosis and pelvic pain patients were evaluated with analysis of variance and Pearson’s χ² tests, as appropriate. Further analysis between subgroups of patients (Endo vs. Pain, Endo vs. Controls; Endo vs. Pain vs. Controls) was performed with Student’s t-test and Pearson’s χ² tests. Results were thresholded at P < 0.05, after performing a domain-specific correction for multiple comparisons (Bonferroni; P < 0.05/number of domains), yielding a threshold of P < 0.017 for 3 domains. Three domains included clinical pain, experimental pain testing, and measures of mood/function.
test with age as nuisance variable, also referred to as parametric cohort analysis).

As the $\text{Endo} \cap \text{Pain}$ and the $\text{Endo} \cap \text{Pain}$ group were 10 years apart in age (group average), each group was analyzed with its own age-adjusted HC group (ie, for the $\text{Endo} \cap \text{Pain}$ group, n = 17; and for the $\text{Endo} \cap \text{Pain}$ group, n = 15). Each of these 2 HC groups were drawn from the pool of 23 HCs. Eight HC participants were included in both control groups. For the 6 $\text{Endo} \cap \text{Pain}$ patients, we matched 12 HCs of the same age, 8 of which were included in the previous HC comparison groups. With respect to the small number of patients in this group, a nonparametric group comparison was performed using the SnPM (Statistical nonParametric Mapping) toolbox, which uses the general linear model and voxel-wise statistics to construct pseudo r-statistic images, and then assesses the data for significance using a nonparametric multiple comparison procedure based on permutation testing (in our case, 5000 permutations). Permutation tests are recommended for designs with low degrees of freedom [24]. The following design module was applied: 2 groups; 2-sample t-test; 1 scan per subject, controlling for age. To avoid possible edge effects around the border between gray and white matter and to include only relatively homogeneous voxels, we excluded all voxels with a GM matter value of <0.1 (maximum value of 1) for both parametric and nonparametric tests.

Statistical maps were corrected for multiple comparisons on the cluster level ($P < 0.05$, derived from an uncorrected voxel level threshold of $P < 0.001$, with a cluster extent of 660 contiguous voxels), as estimated by AlphaSim, an application implemented in the Analysis of Functional Neuroimages software (http://afni.nimh.nih.gov/afni/doc/manual/AlphaSim), which is based on a Monte Carlo simulation (5000 simulations) applied to a whole brain mask (including cortical GM, WM, CSF, brainstem, and cerebellum). As we had a clearly defined a priori hypothesis, looking for GM changes within structures of the pain system and pain modulatory system (midbrain, thalamus, putamen, amygdala, somatosensory cortex, insular cortex, cingulate cortex, and prefrontal cortex); we allowed, in a second step for these regions, a relaxed cluster extent threshold of 200 contiguous voxels. Clusters with an extent between 200 and 660 voxels outside the pain system are reported, as these results could be interesting for future analyses, but will not be further commented on (and should be regarded as uncorrected). Anatomical labeling of brain regions was performed using the SPM5 extension xjview (http://www.alivelearn.net/xjview8/).

To further explore behavioral relevance of changes in regional GM volume, we performed correlation analyses, extracting the eigenvariate from the GM clusters identified in the cohort analyses. This yielded an average GM value for that region in each person; values were then transferred to SPSS (Version 17; IBM Corporation, Armonk, NY, USA), where we performed correlation analyses, correlating extracted GM values with 3 domains of behavioral and pain data:

1. Clinical pain: pain intensity (visual analogue scale) on day of functional MRI scan, GBS pelvic pain intensity and GBS pelvic pain unpleasantness in the last month, and duration of CPP.

2. Experimental pain: pressure needed to elicit faint (0.5 on the GBS), mild (7.5 on the GBS), and/or slightly intense pain (13.5 on the GBS).

3. Mood and physical function measures: anxiety, depression, and physical function component of SF-36.

For the $\text{Endo} \cap \text{Pain}$ group (n = 6) we performed Spearman’s rank correlations due to the small sample size; within the other 2 groups ($\text{Endo} \cap \text{Pain}$ and $\text{Endo} \cap \text{Pain}$), Pearson correlations were performed. Results were thresholded at $P < 0.05$, after performing a domain-specific correction for multiple comparisons (Bonferroni; $P < 0.05$/number of domains), yielding a threshold $P < 0.017$ for all 3 domains. For explorative reasons, correlation analyses were also performed within each group between GM eigenvariates extracted from GM clusters, identified in the cohort analyses, because correlations between GM values in remote brain regions can be an indicator of structural connectivity [17]. No corrections for multiple comparisons were applied in these analyses.

3. Results

3.1. Behavioral data: age, pain, pain thresholds, anxiety, and depression

Descriptive data on age, race, and current hormonal contraceptive use is presented in Table 1. Generally, participants with CPP,
both with and without endometriosis (Endo\textsubscript{P} and Endo\textsubscript{CP}), were young women who were significantly younger than women with endometriosis without CPP.

The surgical history and clinical pain experience of women with endometriosis and/or CPP are presented in Table 2. Although more advanced-stage endometriosis was found in the Endo\textsubscript{P} group when compared to the Endo\textsubscript{CP} group, there was no correlation between endometriosis stage and any other clinical pain characteristic (data not presented). When comparing the 2 subgroups of participants with CPP (Endo\textsubscript{P} and Endo\textsubscript{CP}), there was also no difference in median duration of pelvic pain symptoms ($P = 0.29$), average number of pain days per month ($P = 0.42$), and mean pain intensity before ($P = 0.91$) or during menstruation ($P = 0.98$).

3.2. Results from voxel-based morphometry – cohort analyses and correlations analyses

VBM analyses revealed several regions of GM volume changes in various parts of the brain, while comparing each group to their own matched HC group. In the Endo\textsubscript{P} group, GM volume decrease (in comparison to the HC group) was observed in the left thalamus, left middle frontal gyrus (MFG), bilateral mid cingulate cortex (MCC), right putamen, and right insular cortex. An increase in regional GM volume was observed in the left amygdala. For details, see Table 3 and Fig. 3.

Correlation analyses within the Endo\textsubscript{P} were based on 16 patients because clinical pain data from 1 patient were missing. GM volume decrease in the cingulate gyrus (GM values extracted from the cluster in the MCC identified in the group comparison) correlated with regional GM volume of the left thalamus ($r = 0.56$, $P = 0.024$) and with the regional GM volume of the left MFG ($r = 0.60$, $P = 0.014$). GM values extracted from the MCC cluster correlated negatively with pain unpleasantness ($r = -0.59$, $P = 0.016$); that is, the less GM volume, the more unpleasant pain was perceived; surprisingly, it also correlated negatively with pressure needed to elicit high pain ($r = -0.60$, $P = 0.013$); that is, the less GM volume, the more pressure was needed to elicit a pain score of 13.5 on the GBS. GM values extracted from the thalamus cluster and from the left MFG cluster correlated with MCC GM values (see above) and with pain unpleasantness ($r_{\text{thalamus}} = -0.64$, $P = 0.008$; $r_{\text{MCC}} = -0.53$, $P = 0.037$; also see Fig. 4). Finally, GM values extracted from the cluster found in the right posterior IC also correlated negatively with pain unpleasantness ($r_{\text{IC}} = -0.59$, $P = 0.017$). Neither anxiety nor depression scores were significantly correlated with GM values of any of the clusters. There was also no significant correlation between pain duration and GM volume in any cluster.

In the Endo\textsubscript{CP} group, decreased GM volume (relative to HCs) was observed only in the right inferior temporal gyrus. Furthermore, this group showed an increase in regional GM volume in several regions, including the right periaqueductal gray (PAG), right inferior frontal gyrus, and right MFG. For details, see Table 3 and Fig. 3. There was a trend for a positive correlation between pressure needed to elicit mild pain (7.5 on the GBS) and regional GM volume in the right PAG cluster (identified in the group comparison with HCs; $r = 0.53$, $P = 0.042$); that is, the higher the GM values the more pressure was needed to elicit mild pain. Regional GM values in the right MFG correlated positively with regional PAG GM values ($r = 0.54$, $P = 0.04$) and also with pressure needed to elicit low pain (0.5 on the GBS, $r = 0.60$, $P = 0.019$).

In the Endo\textsubscript{CP} group, GM volume decrease was observed in the left thalamus when compared to HCs. There was a highly significant negative correlation between regional left thalamus volume and pain ratings during menstruation ($r = -0.94$, $P = 0.003$). Again, there was no significant correlation between pain duration and GM volume in any cluster in the Endo\textsubscript{CP} group.

4. Discussion

The current study sought to investigate changes in regional brain morphology in patients with CPP, with and without endometriosis, as an attempt to disentangle the interaction between chronic pain, endometriosis, and changes in brain morphology. A decrease in regional GM volume in the thalamus was found in
patients with CPP, regardless of the presence of endometriosis. Furthermore, patients with CPP and endometriosis showed decreased GM volume in the right posterior insula, the right putamen, and the MCC. Decreases in GM in the thalamus, MCC, and IC correlated with pain unpleasantness in this group. Endometriosis patients without CPP showed no evidence of a GM decrease within the pain system, instead, an increase in regional GM volume was observed in the mesencephalon (PAG) and the right prefrontal cortex.

Our results are well in line with other VBM studies reporting decreases in GM in chronic pain patients, including other pelvic pain conditions, in regions of the pain system (thalamus, IC, CC) and/or those involved in pain modulation (prefrontal cortex) [6,8,10,33,40]. Interestingly, a similar pattern of regional GM decrease has been observed in patients suffering from irritable bowel syndrome (IBS), with decreased volume in various cortical and subcortical structures, such as the anterior CC, MCC, IC, prefrontal cortex, putamen, and thalamus [6,8,34]. Seminowicz et al. described decreases in GM volume in the thalamus bilaterally in IBS patients, close to where thalamic GM decrease was found in this study [34]. Although our images do not have sufficient resolution to distinguish nuclei, the thalamic GM decrease seems to involve the medial nuclei. These nuclei are structurally connected with the prefrontal cortex and the anterior IC, and have been proposed to be part of a visceral pain network. Interestingly, in the Endo Pain group, regional GM volume in the thalamus correlated with regional MCC volume (and both were negatively correlated with pain unpleasantness), suggesting that pain in this cohort involves a network [17]. It is conceivable that both pain syndromes, CPP and IBS, share a common underlying pathophysiology resulting in disturbed viscerosensation; that is, (re)organization of the thalamus allows normally “silent” visceral/propioreceptive signals to be processed differently, gain (increased) access to higher cortical structures, and be perceived as painful.

Particularly relevant to this study is the growing line of evidence that altered brain morphology and function is already present in patients with dysmenorrhea [40,41,44], which is often reported prior to transitioning to CPP. Against this background, dysmenorrhea can be considered a precursor stage for some women who progress to CPP. For example, Vincent et al. reported altered CNS response to noxious stimuli in women with dysmenorrhea that persists beyond the time of menstruation, when women do not report pain [44]. Tu et al. described changes in regional cerebral metabolism in women with dysmenorrhea in the thalamus bilaterally [41]. These women also displayed increases in GM volume in the MCC, secondary somatosensory cortex, hippocampus, hypothalamus, and mesencephalon [40]. Interestingly, the increase in the MCC projected near the cluster of GM decrease found in our study, which has been described in other chronic pain states [20,30]. Furthermore, the regional increase in GM in the mesencephalon matched the increase in GM found in the Endo Pain group in the current study; both clusters projected to the PAG, a key structure in the antinociceptive system. As such, it is tempting to hypothesize that despite endometriosis serving as a cyclic pain generator, the Endo Pain group experienced little if any (cyclic) pain, due to adaptive changes in the PAG, possibly due to increased antinociceptive capacity. In support of this hypothesis, we found that PAG volume showed a trend to be positively correlated with pressure needed to elicit mild pain, suggesting a relationship between PAG volume and pressure pain thresholds.

4.1. Endometriosis, dysmenorrhea, and CPP – a conceptual approach to pain chronification

Endometriosis is an important risk factor for CPP, and it is well accepted that endometriosis can act as a nociceptive source and peripheral pain generator during menses, often leading to cyclic pelvic pain (dysmenorrhea). However, it remains unclear why only some women undergo a transition to a chronic pain state, while others do not. One might argue that endometriosis is the only source of pain, and that the pain experienced in these women outside of the menses is due to an ongoing neuroinflammatory process in the pelvis. In such a scenario, chronic pain is conceptually understood as being the result of an ongoing nociceptive input (defined here as a peripherally generated, neural input using nociceptive pathways, such as C and Aδ fiber) to an otherwise normal brain. However, this hypothesis has recently been challenged by several authors who summarize the increasing evidence that the mechanism of pelvic pain in women with endometriosis may be partly related to CNS amplification of pain processing [19,37]. This process of central pain modulation (amplification or inhibition) could explain why some women suffer from dysmenorrhea and/or CPP but do not have an identifiable peripheral nociceptive input.
while other women with endometriosis (even severe) experience little if any pain.

The hallmark of chronic pain seems to be a decrease in GM volume in structures known to be part of the pain system, although increases in regional GM have been described in some studies, mainly in the basal ganglia [31,33,47]. These changes in GM volume may vary between pain states and brain structures involved, and each might depend on pain duration, pain occurrence (intermittent vs. persistent), personality traits, and medication; as such, the current literature is inconclusive. However, it is also possible that GM changes are dynamic and change over time within an individual. For example, some recent longitudinal studies suggest that GM changes can be induced by repeated experimental pain [39], and that changes associated with clinical pain can reverse spontaneously [25] and/or after removal of the nociceptive source [15]. Given that changes in regional brain morphology are not preexisting in the few published longitudinal studies, but develop after repeated noxious input, it is possible that the initial “reaction” of the brain is a GM increase in certain pain-transmitting areas, such as the MCC and the somatosensory cortex, as well as changes in regional metabolism (thalamus) [39–41]. This initial increase in GM might at first be an adaptive mechanism. Dependent on the duration and persistence of the nociceptive input, local characteristics of the neural tissue and other factors such as capacity/effectiveness of antinociceptive systems, a transition to a chronic pain state might then take place in some patients, which is marked by a decrease in regional gray matter volume in the pain system. These changes, once they occur, may then contribute to an ongoing pain perception, even after disappearance/removal of the initial nociceptive source.

Whether pain becomes chronic depends on the interaction of various factors, namely the persistence of the peripheral pain generator, the antinociceptive capacity, and (maladaptive) neuroplasticity of the pain system. Given that dysmenorrhea is often a


pre-stage of CPP, our data and those of others suggest that pain chronification is marked by a decrease in regional GM volume in the pain system. Those women that remain relatively “pain-free,” on the other hand, do not show these decreases. In contrast, they show an increase in GM volume in the antinociceptive system, which again might be adaptive. A conceptual model summarizing the possible relationship between dysmenorrhea and factors associated with the progression to CPP is presented in Fig. 5.

4.2. Limitations

The group of Endo Pain patients was rather small (n = 6). Although we tried to address this issue by performing nonparametric tests, a larger sample size is preferable. The small sample in this subgroup is due to the fact that endometriosis is highly prevalent in the CPP clinic that referred patients to this research protocol (70%-80%), and the strict inclusion criteria that were required of this subgroup. For obvious reasons, not all of the HCs had been explored via laparoscopy. Given a general population prevalence of endometriosis of 5%-10%, we estimate that 1-2 HCs had undiagnosed endometriosis. However, given this small number and substantial differences seen between patient and HC subgroups, we would not expect this small misclassification error to significantly influence our results. Finally, the cross-sectional design of this study precludes the ability to determine whether the changes in GM volume are a cause or consequence of the pain experience. Longitudinal studies are needed to better address this important question.

4.3. Conclusions

The current study adds to the growing body of literature suggesting that chronic pain states are associated with changes in regional brain morphology. Our data challenge the idea of endometriosis being the only and direct cause of pelvic pain in women with endometriosis-associated CPP, suggesting that central mechanisms as reflected by changes in regional brain morphology, such as thalamic GM decrease, play a pivotal role. Whether in the pre-stage of CPP, our data and those of others suggest that pain chronification is marked by a decrease in regional GM volume in the pain system. Those women that remain relatively “pain-free,” on the other hand, do not show these decreases. In contrast, they show an increase in GM volume in the antinociceptive system, which again might be adaptive. A conceptual model summarizing the possible relationship between dysmenorrhea and factors associated with the progression to CPP is presented in Fig. 5.

4.2. Limitations

The group of Endo Pain patients was rather small (n = 6). Although we tried to address this issue by performing nonparametric tests, a larger sample size is preferable. The small sample in this subgroup is due to the fact that endometriosis is highly prevalent in the CPP clinic that referred patients to this research protocol (70%-80%), and the strict inclusion criteria that were required of this subgroup. For obvious reasons, not all of the HCs had been explored via laparoscopy. Given a general population prevalence of endometriosis of 5%-10%, we estimate that 1-2 HCs had undiagnosed endometriosis. However, given this small number and substantial differences seen between patient and HC subgroups, we would not expect this small misclassification error to significantly influence our results. Finally, the cross-sectional design of this study precludes the ability to determine whether the changes in GM volume are a cause or consequence of the pain experience. Longitudinal studies are needed to better address this important question.

4.3. Conclusions

The current study adds to the growing body of literature suggesting that chronic pain states are associated with changes in regional brain morphology. Our data challenge the idea of endometriosis being the only and direct cause of pelvic pain in women with endometriosis-associated CPP, suggesting that central mechanisms as reflected by changes in regional brain morphology, such as thalamic GM decrease, play a pivotal role. Whether in the pre-stage of CPP, our data and those of others suggest that pain chronification is marked by a decrease in regional GM volume in the pain system. Those women that remain relatively “pain-free,” on the other hand, do not show these decreases. In contrast, they show an increase in GM volume in the antinociceptive system, which again might be adaptive. A conceptual model summarizing the possible relationship between dysmenorrhea and factors associated with the progression to CPP is presented in Fig. 5.

4.2. Limitations

The group of Endo Pain patients was rather small (n = 6). Although we tried to address this issue by performing nonparametric tests, a larger sample size is preferable. The small sample in this subgroup is due to the fact that endometriosis is highly prevalent in the CPP clinic that referred patients to this research protocol (70%-80%), and the strict inclusion criteria that were required of this subgroup. For obvious reasons, not all of the HCs had been explored via laparoscopy. Given a general population prevalence of endometriosis of 5%-10%, we estimate that 1-2 HCs had undiagnosed endometriosis. However, given this small number and substantial differences seen between patient and HC subgroups, we would not expect this small misclassification error to significantly influence our results. Finally, the cross-sectional design of this study precludes the ability to determine whether the changes in GM volume are a cause or consequence of the pain experience. Longitudinal studies are needed to better address this important question.

4.3. Conclusions

The current study adds to the growing body of literature suggesting that chronic pain states are associated with changes in regional brain morphology. Our data challenge the idea of endometriosis being the only and direct cause of pelvic pain in women with endometriosis-associated CPP, suggesting that central mechanisms as reflected by changes in regional brain morphology, such as thalamic GM decrease, play a pivotal role. Whether in the pre-stage of CPP, our data and those of others suggest that pain chronification is marked by a decrease in regional GM volume in the pain system. Those women that remain relatively “pain-free,” on the other hand, do not show these decreases. In contrast, they show an increase in GM volume in the antinociceptive system, which again might be adaptive. A conceptual model summarizing the possible relationship between dysmenorrhea and factors associated with the progression to CPP is presented in Fig. 5.

4.2. Limitations

The group of Endo Pain patients was rather small (n = 6). Although we tried to address this issue by performing nonparametric tests, a larger sample size is preferable. The small sample in this subgroup is due to the fact that endometriosis is highly prevalent in the CPP clinic that referred patients to this research protocol (70%-80%), and the strict inclusion criteria that were required of this subgroup. For obvious reasons, not all of the HCs had been explored via laparoscopy. Given a general population prevalence of endometriosis of 5%-10%, we estimate that 1-2 HCs had undiagnosed endometriosis. However, given this small number and substantial differences seen between patient and HC subgroups, we would not expect this small misclassification error to significantly influence our results. Finally, the cross-sectional design of this study precludes the ability to determine whether the changes in GM volume are a cause or consequence of the pain experience. Longitudinal studies are needed to better address this important question.

4.3. Conclusions

The current study adds to the growing body of literature suggesting that chronic pain states are associated with changes in regional brain morphology. Our data challenge the idea of endometriosis being the only and direct cause of pelvic pain in women with endometriosis-associated CPP, suggesting that central mechanisms as reflected by changes in regional brain morphology, such as thalamic GM decrease, play a pivotal role. Whether in the pre-stage of CPP, our data and those of others suggest that pain chronification is marked by a decrease in regional GM volume in the pain system. Those women that remain relatively “pain-free,” on the other hand, do not show these decreases. In contrast, they show an increase in GM volume in the antinociceptive system, which again might be adaptive. A conceptual model summarizing the possible relationship between dysmenorrhea and factors associated with the progression to CPP is presented in Fig. 5.

4.2. Limitations

The group of Endo Pain patients was rather small (n = 6). Although we tried to address this issue by performing nonparametric tests, a larger sample size is preferable. The small sample in this subgroup is due to the fact that endometriosis is highly prevalent in the CPP clinic that referred patients to this research protocol (70%-80%), and the strict inclusion criteria that were required of this subgroup. For obvious reasons, not all of the HCs had been explored via laparoscopy. Given a general population prevalence of endometriosis of 5%-10%, we estimate that 1-2 HCs had undiagnosed endometriosis. However, given this small number and substantial differences seen between patient and HC subgroups, we would not expect this small misclassification error to significantly influence our results. Finally, the cross-sectional design of this study precludes the ability to determine whether the changes in GM volume are a cause or consequence of the pain experience. Longitudinal studies are needed to better address this important question.

Conflict of interest statement

D.J. Clauw declares associations with the following companies: Cypress Bioscience, Eli Lilly and Company, Forest Laboratories, Pierre Fabre Médicament, Pfizer, Procter & Gamble, Novu, Jazz, Johnson and Johnson, Merck, and Wyeth Pharmaceuticals. See the article online for full details of these relationships. The other authors declare no competing interests. R. E. Harris has received consulting fees and grant support from Pfizer.

Acknowledgments

This work was supported in part by the following research grants: NIH Building Interdisciplinary Research in Women’s Health K12HD001438, NIH UL1RR024986; Bayer Drogemueller Award in Clinical Research, NIH R01-AR050044, and DAMD 17-00-2-0018. Tobias Schmidt-Wilcke is currently supported by a grant from the DFG (Deutsche Forschungsgemeinschaft, GZ: SchM 2665/1-1). Richard Harris is supported by grants from the Dana Foundation.
and the Department of Defense (Army Grant: DAMD-W81XWH-07-2-0050). Vitaly Napadow and Jeun Kim were supported by NCCAM, NIH (RO1-AT004714 [Napadow], P01-AT002048 [Rosen]).

References